- Home
- HKPD vs CLDI Comparison
HKPD vs CLDI Comparison
Compare HKPD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKPD | CLDI |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | United States |
| Employees | 27 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HKPD | CLDI |
|---|---|---|
| Price | $0.62 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.4K | ★ 275.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.22 |
| 52 Week High | $2.74 | $7.32 |
Technical Indicators
Market Signals| Indicator | HKPD | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 19.87 |
| Support Level | N/A | $0.22 |
| Resistance Level | $0.89 | $0.90 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 19.98 | 2.24 |
Price Performance
Historical ComparisonAbout HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.